A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy

British Journal of Cancer

Volumn 109, Issue 4, 2013, Pages 859-865

  Tanioka, M ^a,b   Kitao, A ^a   Matsumoto, K ^a   Shibata, N ^a   Yamaguchi, S ^a   Fujiwara, K ^a   Minami, H ^b   Katakami, N ^c   Morita, S ^d   Negoro, S ^a  

^a HYOGO CANCER CENTER   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; GRANISETRON; IRINOTECAN; PACLITAXEL; PEMETREXED; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MODERATELY EMETOGENIC CHEMOTHERAPY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOMETRIAL NEOPLASMS; FEMALE; GRANISETRON; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MORPHOLINES; NEOPLASMS; OVARIAN NEOPLASMS; TEMPERANCE; TREATMENT OUTCOME; VOMITING;

EID: 84883159933     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.400     Document Type: Article

References (27)

1. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2012) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29: 4189-4198.
2. Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba SG (2012) Antiemesis. J Natl Compr Canc Netw 10: 456-485.
3. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358: 2482-2494.
4. Hesketh PJ, Aapro M, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18: 1171-1177.
5. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, De Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-The Aprepitant Protocol 052 Study Group. J Clin Oncol 21: 4112-4119.
6. IGAR (1998) Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 16: 2937-2942.
7. Ioannidis JP, Hesketh PJ, Lau J (2000) Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-Analysis of randomized evidence. J Clin Oncol 18: 3409-3422.
8. Kerdelhue B, Gordon K, Williams R, Lenoir V, Fardin V, Chevalier P, Garret C, Duval P, Kolm P, Hodgen G, Jones H, Jones GS (1997) Stimulatory effect of a specific substance P antagonist (RPR 100893) of the human NK1 receptor on the estradiol-induced LH and FSH surges in the ovariectomized cynomolgus monkey. J Neurosci Res 50: 94-103.
9. Kerdelhue B, Williams RF, Lenoir V, Fardin V, Kolm P, Hodgen GD, Jones GS, Scholler R, Jones Jr. HW (2000) Variations in plasma levels of substance P and effects of a specific substance P antagonist of the NK(1) receptor on preovulatory LH and FSH surges and progesterone secretion in the cycling cynomolgus monkey. Neuroendocrinology 71: 228-236.
10. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24: 2932-2947.
11. Lagiou P, Tamimi R, Mucci LA, Trichopoulos D, Adami HO, Hsieh CC (2003) Nausea and vomiting in pregnancy in relation to prolactin, estrogens, and progesterone: a prospective study. Obstet Gynecol 101: 639-644.
12. Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9: 188-195.
13. Nerenz DR, Leventhal H, Easterling DV, Love RR (1986) Anxiety and drug taste as predictors of anticipatory nausea in cancer chemotherapy. J Clin Oncol 4: 224-233.
14. Oo TH, Hesketh PJ (2005) Drug insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting. Nat Clin Pract Oncol 2: 196-201.
15. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15: 116-123.
16. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, JulieMa G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97: 3090-3098.
17. Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatininduced emesis. Definition and validation of a predictive logistic model. Cancer 64: 1117-1122.
18. Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18: 423-431.
19. Roila F, Fatigoni S (2006) New antiemetic drugs. Ann Oncol 17(Suppl 2): ii96-100.
20. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy-And radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5): v232-v243.
21. Roscoe JA, Heckler CE, Morrow GR, Mohile SG, Dakhil SR, Wade JL, Kuebler JP (2012) Prevention of delayed nausea: a university of Rochester cancer center community clinical oncology program study of patients receiving chemotherapy. J Clin Oncol 30: 3389-3395.
22. Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17: 1000-1006.
23. Schwartzberg LS (2007) Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J Support Oncol 5: 5-12.
24. Villablanca AC, Hanley MR (1997) 17beta-estradiol stimulates substance P receptor gene expression. Mol Cell Endocrinol 135: 109-117.
25. Walsh JW, Hasler WL, Nugent CE, Owyang C (1996) Progesterone and estrogen are potential mediators of gastric slow-wave dysrhythmias in nausea of pregnancy. Am J Physiol 270: G506-G514.
26. Waqar MA, Chitneni P, Williams K, Goodgame BW, Gao F, Govindan R, Baggstrom MQ (2008) A prospective study on the incidence of delayed nausea and vomiting following administration of carboplatin containing regimens for treatment of cancer without prophylactic aprepitant. J Clin Oncol (Meeting Abstracts) 26: 20626.
27. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23: 2822-2830.